Filing search / Phathom Pharmaceuticals, Inc. / "R&D"

8-K

EX-99.1

PHAT Phathom Pharmaceuticals, Inc.

6 Mar 25

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

8:05am

. Research and development (R&D) expenses: R&D expenses for the fourth quarter 2024 were $8.6 million, a decrease of $4.8 million compared to $13.4 million … for fourth quarter 2023. R&D expenses for the full year 2024 were $34.1 million, a decrease of $15.8 million compared to $49.9 million in 2023

8-K

EX-99.1

PHAT Phathom Pharmaceuticals, Inc.

7 Nov 24

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

8:05am

. Research and development (R&D) expenses: R&D expenses for the third quarter 2024 were $8.7 million, a decrease of $3.6 million compared to $12.3

8-K

EX-99.1

PHAT Phathom Pharmaceuticals, Inc.

8 Aug 24

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

8:06am

for the second quarter 2023 due to the launch of VOQUEZNA taking place in the fourth quarter 2023. Research and development (R&D) expenses: R&D expenses

8-K

EX-99.1

PHAT Phathom Pharmaceuticals, Inc.

9 May 24

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

8:05am

2023 due to the launch of VOQUEZNA during the fourth quarter 2023. Research and development (R&D) expenses: R&D expenses for the first quarter 2024 were

8-K

EX-99.1

PHAT Phathom Pharmaceuticals, Inc.

7 Mar 24

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

8:06am

. Research and development (R&D) expenses: R&D expenses for the fourth quarter 2023 were $13.4 million, a decrease of $2.5 million compared to $15.9 million … for fourth quarter 2022. R&D expenses for the full year 2023 were $49.9 million, a decrease of $21.5 million compared to $71.4 million in 2022

10-K

5pzhvc4z p6

19 Mar 20

Annual report

8:31am